Convatec has appointed Jens Viebke as a non-executive director, the FTSE 100 medical products company announced on 27 August 2026, with the appointment taking effect immediately. Viebke also joins the board committee that oversees executive remuneration.
Viebke brings more than three decades of senior leadership in the global medical technology industry to the board. He has held executive and leadership roles at major healthcare and medical device groups, including Getinge and GE Healthcare, where he built experience across product development, international commercial operations and the operational discipline that large listed medtech businesses depend on. That background maps closely onto Convatec, whose portfolio spans advanced wound care, ostomy care, continence care and infusion care for patients and clinicians in more than one hundred countries.
The appointment strengthens the independent membership of the board at a time when the company continues to invest in innovation and to expand its presence in higher-growth categories. Adding a director with deep operating experience in medical technology gives the board additional technical depth as it oversees strategy, the research pipeline and a global manufacturing footprint. His place on the remuneration committee also adds industry perspective to how the company structures executive pay and long-term incentives, an area of rising scrutiny for large listed groups.
Convatec framed the appointment as part of the ordinary strengthening and refreshment of its board rather than a response to any single event. For a company that sells into hospital systems and community care settings worldwide, a board that combines financial oversight with genuine sector expertise is an asset, particularly as medical technology is reshaped by digital monitoring, connected devices and new reimbursement models.
Convatec is listed on the London Stock Exchange and is a constituent of the FTSE 100 index. The group has spent recent years sharpening its commercial execution and lifting investment in its product pipeline, and the addition of an experienced medtech operator to its board is consistent with that direction. Viebke takes up the role with immediate effect.
Independent non-executive directors carry particular weight at large listed healthcare companies, where boards must weigh long product development cycles, regulatory approvals across many jurisdictions and the safety and quality obligations that come with making products used in clinical settings. A director who has run medical technology businesses can test management assumptions on those questions with first-hand knowledge rather than from the outside. For Convatec, whose growth depends on continued innovation in categories such as advanced wound care and infusion care, that kind of scrutiny at board level is directly useful.
The company has spent recent years working to lift organic growth, modernise its manufacturing and deepen its pipeline, and it has pointed to chronic care demographics and the shift toward home and community care as long-run tailwinds for its categories. Bringing an experienced operator onto the board as it pursues that agenda adds capacity to oversee execution and capital allocation as the strategy plays out.
